In rare disease research, every patient is precious. That’s why, when Alnylam Pharmaceuticals began development of medicines for rare diseases with few or no treatment options, the company’s leaders knew they needed to design clinical trials that kept patient well-being and disease burden at the forefront.
Alnylam also understood that rare disease patients find hope for the future in their specialists—the principal investigators and affiliated clinical research sites dedicated to finding new treatments and cures. Program leaders sought a solution that would maximize collaboration, communication, and transparency with sites and contract research organizations (CROs)—understanding that, as a young company developing an entirely new class of medicines on its innovative RNAi platform, building trusted relationships with investigators and key opinion leaders would be vital to long-term success.
As Alnylam’s first clinical program began in 2014, the study team saw emerging site-facing technologies as a foundation for those trusted relationships, starting with a purpose-built communication channel and easy-to-use study conduct tools to support a complex protocol.
Alnylam partnered with IQVIA Technologies to utilize the Investigator Site Portal and an experienced services team in its earliest human trials. Previously known as Trial Networks and DrugDev Spark, the Investigator Site Portal includes robust modules for site activation, learning management, document exchange and safety notifications, all tied together with market-leading site communication and engagement capabilities.
To ask questions or provide feedback about this case study, please use the Request Info button below. Be sure to indicate if you’d like to schedule a follow-up discussion or demo.